
Quest Diagnostics announced two advancements in its Quest AD-Detect® blood tests for Alzheimer's disease. The company will add the FDA-cleared Elecsys® pTau217 test, the first single-assay blood test for amyloid pathology, to its portfolio by late 2026. Additionally, Quest is launching a new multi-biomarker AD-Detect test combining pTau217, amyloid beta 42/40, and APOE genetic risk markers, achieving a low 10% indeterminate rate. These tests offer less invasive, cost-effective alternatives to PET scans and cerebrospinal fluid testing, improving access and accuracy for Alzheimer's diagnosis nationwide.